DTIL - Precision BioSciences, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Precision BioSciences, Inc.

302 East Pettigrew Street
Suite A-100
Durham, NC 27701
United States
919 314 5512
https://www.precisionbiosciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees197

Key executives

NameTitlePayExercisedYear born
Mr. Michael AmorosoPres, CEO & Director979.04kN/A1978
Mr. John Alexander Kelly R.Ph.Chief Financial Officer623.58kN/A1967
Mr. Dario ScimecaGen. Counsel & Sec.576.43kN/A1976
Dr. Derek Jantz Ph.D.Co-Founder & Chief Science AdvisorN/AN/A1976
Dr. Jefferson J. Smith Ph.D.Co-Founder & Chief Research OfficerN/AN/A1973
Mr. Shane BartonVP, Corp. Controller & Principal Accounting OfficerN/AN/A1971
Mei BurrisDirector of Investor Relations & Fin.N/AN/AN/A
Mr. Bruce StevensVP of Quality & ComplianceN/AN/AN/A
Maurissa MessierSr. Director of Corp. CommunicationsN/AN/AN/A
Ms. Juli BlancheChief People OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Corporate governance

Precision BioSciences, Inc.’s ISS governance QualityScore as of 1 June 2023 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.